Zydus Lifesciences To Launch Semaglutide Injection In India On Patent Expiry

Zydus Lifesciences is preparing to introduce semaglutide injection in India on the very first day of patent expiry, marking a significant milestone in the domestic pharmaceutical industry. Semaglutide, a breakthrough drug widely used for managing type 2 diabetes and obesity, has gained global attention for its efficacy in blood sugar control and weight reduction.  

By launching the product promptly, Zydus aims to provide Indian patients with affordable access to advanced treatment options that have so far been dominated by multinational pharmaceutical companies. The company’s strategy underscores its commitment to innovation and timely delivery of critical therapies.  

Industry experts believe that Zydus’ entry into the semaglutide market could reshape the competitive landscape, driving affordability and accessibility in India’s healthcare sector. The launch also highlights the growing importance of domestic pharmaceutical firms in bridging gaps between global innovation and local patient needs.  

Key Highlights  
Zydus Lifesciences to launch semaglutide injection in India  
Launch scheduled on day one of patent expiry  
Drug widely used for diabetes and obesity management  
Affordable alternative to global treatments  
Expected to reshape India’s pharmaceutical market dynamics  

Sources: Reuters, Economic Times, Mint